Suven Life Sciences Limited

Key Highlights

Financial Snapshot

Suven Life Sciences reported a consolidated net loss of Rs. 106.94 crore (Rs. 10,694.21 lakh) for the quarter ended September 30, 2026, compared to a loss of Rs. 77.31 crore (Rs. 7,730.99 lakh) in the corresponding quarter of the previous year. The revenue from operations stood at Rs. 1.20 crore (Rs. 119.86 lakh). The company does not operate in multiple segments, focusing entirely on Research & Development.

Clinical Development Pipeline

The company provided updates on several key clinical programs:

• SUVN-502 (Masupirdine): Enrollment for the Global Phase 3 trial in Alzheimer's Dementia is complete. The company expects the last patient visit in Q1 2027, with topline data potentially in Q2 2027.
• SUVN-G3031 (Samelisant): A global Phase 3 study for narcolepsy is currently in progress.
• SUVN-911 (Ropanicant): The Phase 2B clinical study in the USA is complete with a successful outcome; the company is targeting the initiation of a global Phase 3 program in Q2 2027.
• SUVN-D4010 (Usmarapride): A Phase 2 Proof of Concept study for cognitive dysfunction was initiated in October 2026.
• SUVN-I6107: Phase 1 safety and pharmacokinetic studies are complete, and Phase 2 enabling toxicology studies are underway.

Concerns and Watch Points

• Cash Burn: The company continues to incur substantial R&D expenses (Rs. 100.30 crore / Rs. 10,029.99 lakh consolidated for the quarter) with minimal operational revenue, which remains the primary operational focus for investors.
• Execution Dependency: The advancement of the pipeline is subject to successful trial outcomes and future regulatory milestones, which are inherently uncertain.

Investor Takeaway

The quarterly results are consistent with the company's business model as a pre-commercial biopharmaceutical developer. Shareholders should prioritize progress in the clinical pipeline—specifically the upcoming data readouts and initiation of Phase 3 studies—as these represent the primary drivers for long-term value creation.

Key Highlights

Financial Snapshot (Consolidated)

The company reported a consolidated net loss of Rs. 106.94 crore for the quarter ended September 30, 2026, widening from the loss of Rs. 77.31 crore reported in the same quarter last year. Revenue from operations for the quarter was Rs. 1.20 crore, compared to Rs. 0.92 crore in the year-ago period.

Note: Figures are converted from Lakhs to Crores for readability.

R&D Pipeline Progress

Suven Life Sciences provided status updates on its ongoing clinical development programs for CNS disorders:

• SUVN-502 (Masupirdine): Enrollment milestone completed for the Global Phase 3 trial for agitation in Alzheimer’s dementia. Topline data reporting is anticipated in Q2 2027.
• SUVN-G3031 (Samelisant): Global Phase 3 study for narcolepsy is currently in progress.
• SUVN-911 (Ropanicant): Phase 2B clinical study in the USA is completed with a successful outcome; the company is targeting the initiation of a Global Phase 3 program in Q2 2027.
• SUVN-D4010 (Usmarapride): Phase 2 Proof of Concept (PoC) study for cognitive dysfunction was initiated in October 2026.
• SUVN-I6107: Phase 1 safety and pharmacokinetics studies are completed, with Phase 2 enabling toxicity studies currently underway.

Investor Takeaway

The company continues to operate with a primary focus on R&D, reflected in high expenses relative to revenue. Investors should monitor the progress of the clinical pipeline, particularly the transition of key candidates to Phase 3 trials and expected data reporting in 2027, as these represent the core value drivers for the business.

Board Meeting Details

Suven Life Sciences Ltd has scheduled a meeting of its Board of Directors on Thursday, November 5, 2026. The objective of the meeting is to consider and approve the unaudited financial results, both standalone and consolidated, for the quarter and half-year ended September 30, 2026.

Insider Trading Window Update

The company has confirmed that the trading window for dealing in its securities has been closed effective from October 1, 2026. This closure will remain in effect until 48 hours after the formal declaration of the financial results for the quarter and half-year ended September 30, 2026. This measure is in compliance with the company's Code of Conduct for the Prohibition of Insider Trading.

Publication Details Suven Life Sciences Ltd has issued a public notice in English and Telugu newspapers regarding a special window provided for the re-lodgment of transfer requests for physical shares. This initiative complies with SEBI circular guidelines to facilitate the ease of investing for shareholders. ## Regulatory Context The notice is issued pursuant to SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/ I/3750/2026, dated January 30, 2026. The company is offering a one-time special window to address previous rejections or returns of transfer requests. ## Shareholder Instructions This facility applies to shareholders who submitted transfer requests before April 1, 2019, which were subsequently returned or rejected due to documentation deficiencies. The facility is open from February 5, 2026, to February 4, 2027. Re-lodgment will be processed only in dematerialized form. Shareholders must submit the required documents to the Company's Registrar and Share Transfer Agent. ## Contact Information Registrar and Share Transfer Agent: KFin Technologies Limited, Unit: Suven Life Sciences Limited, Selenium Tower-B, Plot 31 & 32, Gachibowli, Financial District, Nanakramguda, Serilingampally, Hyderabad - 500032, Telangana. Email: einward.ris@kfintech.com

Compliance Filing

Suven Life Sciences Ltd has submitted the mandatory compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026.

Certificate Details

The filing includes certificates dated October 1, 2026, issued by the company's Registrar and Share Transfer Agent, Kfin Technologies Limited. These documents certify that the RTA has complied with the requirements regarding the dematerialization and rematerialization of securities during the quarter ended September 30, 2026. The RTA confirms that the necessary details have been furnished to both the National Securities Depository Limited (NSDL) and the Central Depository Services (India) Limited (CDSL), and to the stock exchanges where the company's shares are listed.

Investor Significance

This is a standard, periodic regulatory filing confirming the integrity of the company's share transfer and dematerialization processes. It contains no material business, financial, or strategic developments.

Trading Window Closure

Suven Life Sciences Limited has formally intimated the stock exchanges regarding the closure of its trading window, in compliance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, and the company's internal Code of Conduct.

Key Details

• Effective Date: October 1, 2026
• Scope: Applies to all designated persons, their immediate relatives, and connected persons.
• Duration: The window will remain closed until 48 hours after the declaration of the company's unaudited financial results for the quarter and half-year ended September 30, 2026.

Investor Note

This is a standard procedural requirement and does not carry implications for the company's performance or business outlook. The company has indicated that it will communicate the date of the board meeting to consider and approve the financial results for the period ended September 30, 2026, in due course.

Key Highlights

Clinical Trial Progress

Suven Life Sciences has successfully concluded patient enrollment for its global Phase-3 study of Masupirdine. The study, which is multicenter, randomized, double-blind, and placebo-controlled, randomized a total of 424 patients, surpassing the protocol's initial design target of approximately 375 patients. Patients were randomized in a 1:1:1 ratio to receive either 50 mg of Masupirdine, 100 mg of Masupirdine, or a placebo daily for 12 weeks.

Future Milestones

The company has outlined a clear timeline for the completion of the trial and data disclosure:

• Last Patient Last Visit (LPLV): Expected by the end of December 2026.
• Database Lock (DBL): Expected by the end of March 2027.
• Topline Results: Expected by May 2027.

Management Commentary

Mr. Venkat Jasti, Chairman and Managing Director, stated that the strong enrollment highlights the unmet need for new treatment options in AAD. The company remains optimistic about the study's completion timeline.

Ramakrishna Nirogi, President and Chief Scientific Officer, highlighted the drug's mechanism as a highly selective 5-HT6 receptor antagonist with a differentiated pharmacological profile. He noted that current treatments for agitation in Alzheimer's patients often rely on sedatives or antipsychotics, which carry risks such as cardiac issues, and Masupirdine aims to address these limitations.

What This Means for Investors

For shareholders, this update confirms the successful execution of the trial recruitment phase, which is a significant de-risking event for the Masupirdine program. The attention now shifts to the trial's completion and the release of topline efficacy and safety data scheduled for May 2027. The higher-than-target enrollment suggests strong site engagement and participant interest in this study.

Key Highlights

Financial Utilization Status

As of June 30, 2026, Suven Life Sciences Limited has successfully utilized ₹409.50 crore (Rs 40,950.29 lakh) of the total proceeds raised through the preferential issue. The remaining unutilized corpus of ₹448.14 crore (Rs 44,813.73 lakh) is being managed through treasury instruments. The monitoring agency has confirmed there are no material deviations from the objects stated in the offer document, indicating the company's adherence to its initial financial plan.

Deployment of Unutilized Proceeds

The unutilized funds are parked in conservative instruments to generate returns while maintaining liquidity. The total amount invested in these instruments as of the quarter-end stood at ₹457.88 crore (Rs 45,788.35 lakh), with a current market value of ₹468.29 crore (Rs 46,828.97 lakh). The company generated earnings of ₹10.41 crore (Rs 1,040.62 lakh) during the quarter from these investments.

Progress on Objects

The proceeds were allocated towards clinical development, R&D infrastructure, and general corporate purposes. Notable progress includes:

• Clinical Development (Suven Neurosciences, Inc.): The company has utilized funds for clinical development of molecules in its research pipeline. During the quarter, a significant portion of funds was deployed to support this overseas subsidiary.
• R&D and CAPEX: Investments were directed towards enhancing Drug Discovery R&D and building a new R&D centre infrastructure.
• General Corporate Purpose (GCP): Utilization included expenses for ordinary course business operations, such as rent, employee benefits, and power/fuel charges.

Investor Takeaway

This monitoring agency report provides assurance that Suven Life Sciences Limited is consistently executing its capital expenditure plan. The absence of any material deviations in fund utilization reflects disciplined treasury management. Investors should note that a significant portion of the funds has been transferred to the company's subsidiary for operational ease to advance its clinical development pipeline. The company continues to earn reasonable returns on its unutilized cash pool, maintaining the capital's value until it is required for core R&D activities.

Regulatory Compliance Update

Suven Life Sciences Limited has published its un-audited financial results for the quarter ended June 30, 2026, in newspapers. This action was taken pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Publication Details

Investor Access

As part of this regulatory disclosure, the company has confirmed that the detailed financial results are available for public review. Investors can access the full information through:

• The company's official website: www.suven.com
• The respective stock exchange portals (BSE and NSE).

Investor Takeaway

This filing is a standard procedural requirement and does not contain new financial data beyond what has already been submitted to the stock exchanges. Existing shareholders should note that this is a routine compliance update ensuring transparency and public access to financial statements.

Financial Snapshot

R&D and Financial Analysis

The company's financials remain dominated by R&D investments, which are essential for its clinical pipeline. Consolidated R&D expenses for the quarter stood at ₹123.83 crore (₹12,383.10 lakh). This expenditure level is the primary driver of the reported consolidated net loss of ₹127.61 crore (₹12,761.03 lakh). The standalone net loss was significantly lower at ₹16.12 crore (₹1,611.91 lakh), reflecting that the majority of R&D operations are housed within the subsidiary, Suven Neurosciences, Inc.

Clinical Pipeline Updates

Management provided updates on several key clinical programs:

• SUVN-502 (Masupirdine): Global Phase 3 trial for Agitation in Alzheimer’s Dementia has reached 95% enrollment, with completion expected by September 2026.
• SUVN-G3031 (Samelisant): Global Phase 3 trial for Narcolepsy initiated in April 2026.
• SUVN-911 (Ropanicant): Completed Phase 2b trial for Major Depressive Disorder (MDD).
• Other Assets: SUVN-D4010 and SUVN-I6107 are advancing through proof-of-concept design and Phase 1/2 preparation stages, respectively.

Corporate Action: Preferential Issue

The company has successfully raised capital through a preferential warrant issue. As of June 30, 2026:

• Total Amount Received: ₹857.64 crore (₹85,764.02 lakh)
• Amount Utilised: ₹409.50 crore (₹40,950.29 lakh)
• Balance Amount: ₹448.14 crore (₹44,813.73 lakh)

What This Means for Investors

Suven Life Sciences continues to operate as a pure-play R&D entity. Investors should note that the widening losses are an expected outcome of the company's active clinical trials. The primary focus for the market should remain on the execution of these trials—specifically the enrollment and results reporting timeline for Phase 3 assets like Masupirdine. The existing cash balance from the preferential issue provides runway to continue these high-cost clinical development programs.

Investor Takeaway

The Q1 results underscore the company's commitment to advancing its neuro-science pipeline. While consolidated losses have increased, this aligns with the accelerated clinical development schedule. Investors should monitor the progress of the Phase 3 trials, as these remain the central value drivers for the company. The balance of funds from the preferential issue indicates the company is well-capitalized to pursue its current research roadmap.

Financial Snapshot

R&D and Financial Analysis

The company's financials highlight its focus on clinical development. Consolidated R&D expenses for the quarter were ₹123.83 crore (₹12,383.10 lakh), significantly higher than the standalone R&D expenditure of ₹12.76 crore (₹1,275.60 lakh). This disparity underscores the heavy investment in clinical trials conducted by the subsidiary, Suven Neurosciences, Inc.

Corporate Action Details

The company provided an update regarding proceeds from its preferential issue. As of June 30, 2026, the cumulative amount received stood at ₹857.64 crore (₹85,764.02 lakh), of which ₹409.50 crore (₹40,950.29 lakh) has been utilised, leaving a balance of ₹448.14 crore (₹44,813.73 lakh).

Concerns and Watch Points

What This Means for Investors

Suven Life Sciences is in a phase of heavy investment in its research and clinical development pipeline. The consolidated losses are largely a function of these R&D efforts. The preferential issue has provided a significant cash cushion, which the company is actively deploying for its clinical programs. Investors should continue to monitor the clinical trial milestones and the efficiency of capital deployment as the company advances its pipeline.

Investor Takeaway

The Q1 FY2027 update highlights the company's operational status as a research-focused entity with significant R&D spending. The preferential issue provides necessary runway, but the company's long-term financial health remains tied to the success of its clinical development programs. Investors should track updates on pipeline milestones.

37th Annual General Meeting Details

Suven Life Sciences Limited has formally announced the convening of its 37th Annual General Meeting (AGM). The meeting is scheduled to be held on Tuesday, August 25, 2026, at 11:30 a.m. IST.

In line with regulatory provisions, the company will conduct the meeting exclusively through Video Conferencing (VC) or Other Audio Visual Means (OAVM).

E-Voting Schedule

The company has provided the following schedule for remote e-voting to enable shareholder participation:

Shareholders who have not cast their votes through remote e-voting will have the opportunity to vote during the AGM through the electronic system provided.

Eligibility and Participation

• Cut-off Date: Tuesday, August 18, 2026. Only shareholders recorded in the Register of Members or the Register of Beneficial Owners as of this date are eligible to participate and vote.
• Attendance: Participation via VC/OAVM will be counted towards the quorum required under Section 103 of the Companies Act, 2013.

Investor Action Items

• KYC Updates: Shareholders are requested to ensure their email addresses, mobile numbers, and KYC details are updated with their respective Depository Participants (DPs) for those holding shares in dematerialized mode.
• Physical Shareholders: Those holding shares in physical mode should submit the prescribed forms (e.g., Form ISR-1) to the company's Registrar and Transfer Agent, KFin Technologies Limited.
• Support: For any queries regarding the e-voting process, shareholders may contact KFin Technologies Limited via the provided toll-free number or dedicated email ID as specified in the AGM notice.

What This Means for Investors

This is a standard procedural update essential for shareholder participation in the upcoming AGM. Investors should ensure their contact information is current with their DPs or the registrar to receive all necessary communication and to participate in the voting process. No immediate financial or business impact is associated with this notice.

Board Meeting Update

Suven Life Sciences Limited has officially informed the stock exchanges regarding a scheduled Board of Directors meeting to address quarterly financial performance.

Meeting Details

Trading Window Closure

In compliance with the Code of Conduct for Prohibition of Insider Trading, the company has implemented a trading window closure to prevent insider trading during the sensitive period surrounding financial results.

• Closure Start Date: July 1, 2026
• Duration: The trading window remains closed until 48 hours after the declaration of the financial results.

Key Highlights

Annual Report Availability

Suven Life Sciences has made its Annual Report for the financial year ended March 31, 2026, available to shareholders. The report can be accessed through the company's website under the 'Investors' section. This disclosure complies with Regulation 36(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Shareholder KYC and Compliance

The company has highlighted a mandatory requirement for all shareholders to maintain updated records. This includes:

• PAN and KYC Details: Postal address with pin code, email address, mobile number, and bank account details.
• Nomination: Necessary to ensure compliance with current SEBI guidelines.

Shareholders are advised to submit these documents to their respective Depository Participant or the Registrar and Transfer Agent (RTA), KFintech, via email at einward.ris@kfintech.com.

Dividend Payment Warning

The company explicitly noted that any payments, including future dividends, for folios where PAN or KYC details are not updated will only be made electronically upon the registration of the required information. Shareholders are encouraged to update their records promptly to avoid potential delays in receipt of corporate benefits.

Senior Citizen Support

The RTA (KFintech) has formed a 'Senior Citizen Investor Cell' exclusively for shareholders aged 60 years and above. This cell is designed to assist in redressing grievances, complaints, and queries. Eligible shareholders can reach out via:

• Email: senior.citizen@kfintech.com
• Toll-Free Number: 1800 3094 006

Investor Takeaway

This announcement is a procedural regulatory disclosure and does not impact the company's business operations or financial outlook. For investors, the primary takeaway is the administrative requirement to ensure KYC and PAN details are updated with the RTA to prevent potential issues regarding the receipt of dividends or other corporate benefits.

Key Highlights

Important Figures Used

Financial and Operational Snapshot

The company's standalone turnover stands at ₹7.11 crore, with a significantly higher net worth of ₹1,503.37 crore. This structure is indicative of a capital-intensive research and development business model, where a large capital base is required to support long-term drug discovery efforts that often yield revenue over extended timeframes.

ESG and Governance

Suven Life Sciences has reaffirmed its commitment to ESG values, particularly in the Central Nervous System (CNS) therapeutic area. The company adheres to international quality certifications, including NABL accreditation, Good Laboratory Practices (GLP), and Good Clinical Practices (GCP). These standards are critical to maintaining scientific integrity and ensuring the reliability of research data.

Management Commentary

The management highlighted the inherent challenges in balancing environmental sustainability with chemical-heavy R&D processes. A key strategic focus remains on meeting medical needs in the CNS area while integrating ESG into the research lifecycle.

Risks and Governance

Clinical trials are identified as a primary material risk, due to the inherent uncertainties in R&D, potential for trial failures, and regulatory scrutiny. The company mitigates these risks through:

• Data Safety Monitoring: Engaging an independent Data Safety Monitoring Board (DSMB) for clinical trials.
• Proactive Risk Assessment: Identifying potential hazards at the start of trials.
• Compliance: Full compliance with applicable environmental laws, including the Water and Air acts.

What This Means for Investors

This report underscores the company's commitment to regulatory compliance and transparency. Investors should monitor the company's ability to manage R&D risks and translate its scientific capabilities into sustained commercial outcomes. The company's heavy reliance on exports (70% of turnover) suggests potential sensitivity to global market dynamics and currency fluctuations.

Investor Takeaway

The release of the BRSR provides clarity on Suven Life Sciences' governance framework and its approach to managing the specific risks associated with drug discovery. Investors should note the company's strong capital base relative to its current turnover, which is characteristic of long-cycle R&D operations. Key areas for tracking include the progress of clinical trials, adherence to ESG targets, and the company's ability to navigate global market conditions for its export-driven services.

Key Highlights

Suven Life Sciences has announced its 37th Annual General Meeting, scheduled for August 25, 2026. The meeting will address financial statement adoption, director re-appointments, and a proposal to vary the utilization of funds raised via a preferential issue.

Preferential Issue Fund Reallocation

The company is seeking shareholder approval to reallocate unutilized proceeds from the Preferential Issue approved in June 2025. This move follows a reassessment of infrastructure needs, where CAPEX requirements for a new R&D center are lower than originally estimated. Funds are being redirected towards clinical development activities in overseas subsidiaries.

Related Party Transaction

Shareholders will vote on the appointment of Dr. Madhavi Jasti to an office of profit in the overseas Wholly Owned Subsidiaries. The role involves overseeing clinical development and medical affairs.

• Proposed Initial Remuneration: USD 400,000 per annum.
• Maximum Aggregate Remuneration: USD 1,000,000 per annum.

Management states this appointment is intended to leverage technical expertise for clinical operations. The company's consolidated turnover for FY 2025-26 was ₹7.11 crore.

Board and Governance Updates

• Re-appointment of Independent Director: Dr. Vajja Sambasiva Rao is proposed for a second five-year term (Jan 21, 2027 – Jan 20, 2032). As he will exceed the age of 75, this requires a Special Resolution.
• Re-appointment of Director: Prof. Seyed E Hasnain is proposed for re-appointment, liable to retire by rotation.

What Looks Positive

• Capital Optimization: The reallocation reflects management's efforts to optimize infrastructure CAPEX and prioritize active clinical trial and R&D activities.
• Monitoring Oversight: The company has appointed CRISIL Ratings Limited as the Monitoring Agency for the preferential issue proceeds, ensuring external oversight of fund utilization.

Concerns and Watch Points

• Remuneration Materiality: The proposed remuneration for Dr. Madhavi Jasti is significant relative to the company's reported consolidated turnover, which investors may wish to review against industry benchmarks.
• Execution Risk: As noted by the company, anticipated benefits of the fund reallocation are subject to clinical trial outcomes, regulatory approvals, and market conditions beyond its control.

Investor Takeaway

The upcoming AGM covers critical operational and governance matters. The proposed reallocation of preferential issue proceeds signals a focus on advancing the clinical development pipeline. Shareholders should review the justifications provided for the related-party transaction and the strategic priorities underlying the fund reallocation. Tracking the progress of clinical trials remains key for assessing the impact of these capital deployment decisions.

Key Highlights

Financial Snapshot

Profitability Analysis

Losses widened on both a standalone and consolidated basis, primarily driven by sustained heavy investment in R&D as the company advances its clinical-stage pipeline. The standalone loss increased from ₹47.08 crore (₹4,707.98 lakh) to ₹54.86 crore (₹5,486.28 lakh). The consolidated loss moved from ₹160.75 crore (₹16,074.50 lakh) to ₹276.34 crore (₹27,634.41 lakh).

Cost and Expense Analysis

Total consolidated expenses reached ₹297.23 crore (₹29,723.11 lakh) in FY 2025-26, compared to ₹178.25 crore (₹17,825.11 lakh) in the previous year. R&D expenditure remains the primary cost component, with consolidated R&D expenses recorded at ₹275.09 crore (₹27,508.92 lakh) for the year.

Corporate Action Details

During the year, the company executed a preferential issue of 6,40,02,999 warrants at an issue price of ₹134 per warrant. As of March 31, 2026, the company had received a total consideration of ₹764.33 crore (₹76,432.53 lakh). Out of this, ₹260.69 crore (₹26,068.64 lakh) was utilized for business requirements, leaving an unutilized balance of ₹503.64 crore (₹50,363.89 lakh) invested in liquid assets.

Clinical Development Status

• Masupirdine (SUVN-502): Phase 3 study for agitation in Alzheimer's dementia reached 95% enrollment.
• Samelisant (SUVN-G3031): Global Phase 3 study initiated in April 2026 for EDS in Narcolepsy.
• Ropanicant (SUVN-911): Successfully completed Phase 2b clinical proof-of-concept trial.
• Usmarapride (SUVN-D4010): Completed Phase 1; Phase 2 trial in planning.
• Tenaclidine (SUVN-I6107): Completed Phase 1; preparing for Phase 2.

What Looks Positive

• Operational Expansion: The new R&D center at Genome Valley is now fully operational, supporting the focus on Central Nervous System (CNS) research.
• Pipeline Advancement: Significant milestones achieved across several molecules, including the initiation of Phase 3 for Samelisant and completion of Phase 2b for Ropanicant.

Concerns and Watch Points

• Financial Performance: Widening losses are a feature of the company's clinical-stage biotech model, requiring careful monitoring of the cash runway and R&D efficiency.
• Clinical Success Dependency: The business is heavily reliant on the success of long-gestation clinical trials. Management has emphasized that clinical results are binary (success or failure).

What This Means for Investors

Suven Life Sciences is in a cash-intensive clinical development phase. Investors should note management's explicit policy of not providing earnings guidance, shifting the focus instead to clinical molecule status. The company's cash position is supported by funds raised through preferential allotment. The upcoming 37th AGM will be a key event for shareholder participation.

Investor Takeaway

The company remains committed to a long-term strategy in CNS drug discovery. For investors, the focus remains on tracking progress in the clinical pipeline (specifically Phase 3 studies) rather than quarterly financial results, given the company's stated policy of providing molecule-status updates instead of earnings guidance.

Shareholding Structure Change

Following the allotment of shares on July 08, 2026, Suven Life Sciences reported a change in the equity capital and a corresponding dilution in the promoter group's shareholding percentage. The company's total equity capital increased as a result of both ESOP exercises and a preferential allotment.

Impact on Promoter Holding

Allotment Details

The changes to the share capital were driven by two primary events:

• Preferential Allotment: The company allotted 1,85,70,133 equity shares to certain identified non-promoter persons or entities.
• ESOP Exercise: The company issued 2,71,970 equity shares following the exercise of vested stock options under the Suven Life Employee Stock Option Scheme 2020.

What This Means for Investors

The disclosure is a standard regulatory filing under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Investors should note that the decline in promoter shareholding is a direct consequence of the expansion of the total share capital through preferential issues and ESOPs. These actions are common corporate mechanisms to raise capital or incentivize employees, leading to equity dilution for existing shareholders, including the promoter group.

Investor Takeaway

This update is primarily a compliance disclosure regarding capital structure changes. For shareholders, the key information is the shift in total outstanding equity shares to 28,25,62,686 and the corresponding adjustment in promoter stake to 65.47%. There is no indication of strategic shifts or unusual activity, as these allotments represent standard corporate actions for equity expansion.

Overview

Suven Life Sciences Limited has published a notice informing shareholders of a special window available for the re-lodgment of physical share transfer requests. This administrative process is being conducted in compliance with the SEBI Circular dated January 30, 2026.

Re-Lodgment Window Details

Compliance and Process

The company is offering this one-time opportunity to facilitate the re-lodgment of share transfer requests that were submitted before April 1, 2019, but were either returned or remained pending due to technical deficiencies in the documentation.

Shareholders whose requests qualify for this special window are advised to coordinate with the company's Registrar and Share Transfer Agent (RTA), M/s KFin Technologies Limited, to complete the process. The company has specified that the re-lodgment must be processed in dematerialized form.

What This Means for Investors

This is a procedural update designed to help shareholders clear legacy paperwork issues related to physical share transfers. It does not carry any financial implications for the company or its operational performance. Existing shareholders holding older physical certificates who previously faced rejection or processing issues regarding share transfers should review their documents and contact the RTA if their specific requests fall within the eligibility criteria.

Scheduled Investor Interaction

Suven Life Sciences Limited has informed the exchanges that its management will be meeting with investors and analysts in an in-person format.

Compliance Note

The company has explicitly stated that no unpublished price-sensitive information (UPSI) will be shared during this scheduled interaction.

What This Means for Investors

This filing is a routine regulatory disclosure as per SEBI requirements regarding planned corporate communications. It provides visibility into the company's ongoing investor relations activity. As with most corporate meeting intimations, it contains no new financial or operational information. Investors should monitor the company's official communications for any material developments that may arise in the future.

Key Highlights

Scientific Poster Presentations

Suven Life Sciences is scheduled to present five scientific posters, providing technical updates on key clinical-stage assets:

• Masupirdine: Updates from the Phase-3 clinical trial program targeting agitation in Alzheimer's dementia.
• Usmarapride: An update on the clinical development program for cognitive disorders.
• SUVN-I6107: Evaluation of safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy human subjects.
• SUVN-L1101142: Muscarinic 4 positive allosteric modulator for Alzheimer's and Schizophrenia.
• SUVN-N9503012: Efficacy and safety for the symptomatic treatment of neurodegenerative disorders.

Strategic Partnering and Business Development

The company is using its presence at AAIC 2026—specifically via Exhibit Booth #117—to facilitate engagement with the global research community, including investigators and key opinion leaders. Management has indicated that a key objective is to explore strategic partnering opportunities for its clinical-stage CNS portfolio with other pharmaceutical and biotechnology companies.

CNS Pipeline Overview

Suven's current clinical-stage portfolio focuses on central nervous system (CNS) disorders, including:

• Masupirdine (SUVN-502): Ongoing global Phase-3 study for agitation in patients with dementia of the Alzheimer's type.
• Samelisant (SUVN-G3031): Focused on narcolepsy (EDS and Cataplexy studies).
• Ropanicant (SUVN-911): Focused on Major Depressive Disorders (MDD).
• Usmarapride (SUVN-D4010): Clinical development for cognitive disorders.
• SUVN-I6107: Phase-1 study completed for cognitive disorders.

In addition to these five clinical-stage assets, the company maintains seven research projects across various indications.

What This Means for Investors

For investors, this update highlights the company's active efforts to advance its neuroscience pipeline and monetize its clinical-stage assets through potential partnerships. As a clinical-stage biopharmaceutical company, Suven's value is significantly tied to the progress of its R&D programs. While this conference participation is a positive step in maintaining visibility within the scientific community, it does not provide immediate financial results. Investors should continue to monitor clinical trial milestones and any formal announcements regarding strategic collaborations or partnerships.

Compliance Filing Update

Suven Life Sciences Limited has filed the required compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2026.

Key Filing Details

What This Means for Investors

This filing is a standard administrative procedure. Under Regulation 74(5), companies and their RTAs must confirm that securities received for dematerialization have been processed and details have been shared with the stock exchanges within the stipulated timelines.

This update confirms that the company is in compliance with these specific regulatory requirements for the quarter. It has no bearing on the company's financial performance, operational strategy, or future outlook.

Investor Takeaway

This is a routine corporate filing and does not require any specific action from investors. It serves as confirmation that the company's share record-keeping processes are following the necessary regulatory guidelines.

Key Highlights

Suven Life Sciences has completed a significant capital raise through a preferential allotment of shares and approved the formation of a new subsidiary in Singapore to boost its clinical research capabilities.

Preferential Allotment

The Board of Directors approved the allotment of 1,85,70,133 equity shares to 17 non-promoter entities. This conversion of warrants was executed at an issue price of ₹134 per share, resulting in an aggregate consideration of ₹248.84 crore (2488.40 lakh) being received by the company. This capital injection strengthens the company's financial position.

Subsidiary Incorporation

The company is expanding its international footprint by incorporating a wholly-owned subsidiary, 'Suven Neurosciences Pte. Ltd.', in Singapore. This entity will focus on bio-pharmaceutical and clinical development, specifically for novel therapeutics targeting neurological disorders. The total investment for this subsidiary is planned to be up to USD 100 million.

Board Update

Dr. Vajja Sambasiva Rao has been re-appointed as a Non-Executive Independent Director for a second five-year term, effective from January 21, 2027, to January 20, 2032, subject to shareholder approval at the ensuing Annual General Meeting.

Investor Takeaway

The successful conversion of warrants provides a substantial cash inflow of ₹248.84 crore (2488.40 lakh), strengthening the balance sheet. The incorporation of the Singapore subsidiary signals a strategic focus on clinical-stage research and international market presence. Investors should track how the deployed capital and the new subsidiary impact the company's R&D progress and long-term financial health.

Key Highlights

Preferential Allotment Details

The Board of Directors approved the allotment of 1,85,70,133 equity shares of face value ₹1/- each at an issue price of ₹134/- per share, including premium. The company has received the full consideration amount of ₹248.84 crore (₹248,83,97,822) from the allottees. This allotment follows the conversion of fully paid warrants.

Impact on Paid-up Equity Share Capital

Strategic Expansion: Singapore Subsidiary

The company is incorporating a wholly-owned subsidiary (WOS) named 'Suven Neurosciences Pte. Ltd.' in Singapore. This entity will operate in the bio-pharmaceutical and clinical development industry, focusing on the acquisition, development, and commercialization of novel therapeutics. The investment amount for this initiative is USD 100 Mn.

Board Update

The Board has approved the re-appointment of Dr. Vajja Sambasiva Rao as a Non-Executive Independent Director for a second term of five years, effective from January 21, 2027, to January 20, 2032, subject to shareholder approval at the ensuing Annual General Meeting.

What Looks Positive

• Capital Infusion: The successful raising of ₹248.84 crore via the preferential issue strengthens the balance sheet.
• Strategic Growth: The commitment of USD 100 Mn for a new subsidiary in Singapore suggests a significant expansion in clinical development capabilities.

Concerns and Watch Points

• Investment Scale: The USD 100 Mn investment in the new Singapore subsidiary represents a substantial capital commitment to clinical-stage biopharmaceutical development, which inherently involves research and regulatory risks.

Investor Takeaway

Suven Life Sciences has taken two major steps: raising ₹248.84 crore through a preferential allotment of 1.85 crore shares and initiating a significant expansion into the Singapore clinical development market with a USD 100 Mn investment. Existing shareholders should monitor how the company deploys this capital, specifically regarding the new subsidiary's development pipeline. The re-appointment of the Independent Director ensures continuity in board oversight. Overall, the combination of a strengthened balance sheet and international expansion plans serves as a key development to track.

Key Highlights

Preferential Allotment

The Board of Directors approved the allotment of 1,85,70,133 equity shares to 17 non-promoter entities. The issue price was set at Rs 134 per share. The company has confirmed receiving 100% of the consideration, amounting to Rs 248.84 crore. This capital infusion increases the paid-up equity share capital of the company from 26,39,92,553 shares to 28,25,62,686 shares.

Strategic Expansion

The company is establishing a wholly-owned subsidiary, 'Suven Neurosciences Pte. Ltd.' in Singapore. This entity is designed as a clinical-stage biopharmaceutical company focusing on the acquisition, development, and commercialization of therapeutics for neurological and other disorders. The company has committed to a total investment of USD 100 million, which will be subscribed in one or more tranches based on business requirements.

Board and Governance

The Board has approved the re-appointment of Dr. Vajja Sambasiva Rao as a Non-Executive Independent Director for a second term of five years, effective from January 21, 2027, to January 20, 2032. This appointment is subject to approval by the members at the ensuing Annual General Meeting.

What Looks Positive

What This Means for Investors

For investors, these developments indicate that Suven Life Sciences is actively strengthening its financial position and expanding its global footprint in the biopharmaceutical sector. The capital raise provides funds for potential growth or operational needs, while the new subsidiary in Singapore suggests a long-term strategic focus on clinical-stage research and development. Investors should track the progress of the new Singapore entity and the deployment of the newly raised capital.

Investor Takeaway

Suven Life Sciences has executed a significant capital raise and a strategic international expansion. The successful receipt of funds from the preferential allotment is a procedural positive. The incorporation of the Singapore-based subsidiary highlights a clear roadmap for clinical-stage development. Shareholders should monitor the company's updates on the operationalization of the new subsidiary and future guidance on how these funds will be deployed in their clinical research pipeline.

Key Highlights

Corporate Action Details

The Board has approved the allotment of 18,570,133 equity shares to 17 non-promoter entities. This preferential issue has resulted in a total capital inflow of ₹248.84 crore (₹24883.98 lakh). The equity shares were issued at a price of ₹134 per share. Following this allotment, the company's total paid-up equity share capital has increased from 263,992,553 shares to 282,562,686 shares.

Transaction Details

Suven Life Sciences is incorporating a wholly-owned subsidiary, 'Suven Neurosciences Pte. Ltd.', in Singapore. The new entity will focus on bio-pharmaceutical clinical development, specifically targeting the acquisition, development, and commercialization of therapeutics for neurological disorders. The company has committed a total investment of USD 100 million to this subsidiary, to be deployed in one or more tranches based on business requirements.

Board Decision or Meeting Update

The Board of Directors also approved the re-appointment of Dr. Vajja Sambasiva Rao as a Non-Executive Independent Director. This appointment is for a second term of five years, effective from January 21, 2027, to January 20, 2032, subject to shareholder approval at the ensuing Annual General Meeting.

What This Means for Investors

This announcement reflects a dual focus on strengthening the balance sheet and expanding R&D operations. The preferential allotment brings in significant external capital from 17 entities, providing the company with resources for future operations. Simultaneously, the establishment of the Singapore subsidiary signals a strategic move to focus on clinical-stage biopharmaceutical development in an international jurisdiction. Investors should monitor how the capital from the preferential issue and the committed USD 100 million are deployed to advance the clinical pipeline.

Investor Takeaway

Suven Life Sciences has effectively raised capital to fund its growth, while also positioning itself for long-term R&D expansion in Singapore. The participation of 17 non-promoter entities in the preferential allotment underscores external confidence. Key focus areas for shareholders going forward will be the operational progress of the new Singapore-based WOS and the impact of the increased equity base on future earnings per share.

Key Highlights

Preferential Share Allotment

Suven Life Sciences has completed the allotment of 1,85,70,133 equity shares on a preferential basis to 17 non-promoter persons and entities. The allotment was made at a price of ₹134 per share. The company has successfully received the full consideration of ₹248.84 crore (₹24,883.98 lakh). This issuance has resulted in an increase in the company's paid-up equity share capital from 26,39,92,553 shares to 28,25,62,686 shares.

International Expansion

The board has approved the incorporation of a wholly-owned subsidiary, 'Suven Neurosciences Pte. Ltd.', in Singapore. This entity will focus on the bio-pharmaceutical and clinical development sector, specifically in the acquisition and development of novel therapeutics for neurological disorders. The company plans an investment of USD 100.00 Mn into this new subsidiary.

Board and Governance

The company announced the re-appointment of Dr. Vajja Sambasiva Rao as a Non-Executive Independent Director. His second term is for a duration of 5 years, effective from January 21, 2027, to January 20, 2032, subject to member approval at the next Annual General Meeting.

Number Relationship Analysis

• Capital Infusion: The preferential allotment of 1,85,70,133 shares has successfully raised ₹248.84 crore (₹24,883.98 lakh). This capital is expected to support the company's broader operational and strategic goals, including the establishment of its new Singaporean subsidiary.
• Capital Structure: The issuance has increased the total paid-up share capital by 1,85,70,133 shares, reflecting the conversion of warrants into equity.

What This Means for Investors

The capital raise of ₹248.84 crore provides the company with substantial liquidity. Investors should monitor how this capital is deployed, particularly regarding the progress of the new Singapore-based subsidiary and its impact on the company's long-term clinical development pipeline. The re-appointment of the independent director provides continuity in board-level governance.

Investor Takeaway

Suven Life Sciences has taken significant steps to bolster its capital base and expand its international operational footprint. With a successful fundraise and a clear strategic pivot toward expanding its clinical-stage capabilities in Singapore, the focus now shifts to the execution of these initiatives. Investors should track the operational progress of the new subsidiary and the deployment of the newly raised funds.

Summary

• Suven Life Sciences Limited has formally submitted a certificate to BSE and NSE regarding compliance with SEBI Regulation 74(5) for the quarter ending March 31, 2026.
• This filing confirms that the company's Registrar and Share Transfer Agent (RTA), Kfin Technologies Limited, has provided the necessary details to stock exchanges (BSE, NSE) and depositories (CDSL, NSDL) regarding the dematerialization and rematerialization of securities during the specified period.
• Key personnel involved include K Sangeetha Laxmi for Suven Life Sciences and C Shobha Anand for Kfin Technologies, acting as Company Secretary and Vice President, respectively.

Key Numbers & Dates

• Reporting Period: Quarter ended March 31, 2026
• RTA Certificate Date: April 01, 2026
• Company Filing Date: April 06, 2026

Summary

• Suven Life Sciences Limited has announced the closure of its trading window for designated persons and their immediate relatives.
• The window will be shut from April 1, 2026, until 48 hours after the company declares its audited financial results for the fourth quarter and fiscal year ended March 31, 2026.

Key Numbers & Dates

• Trading Window Closure Start: April 1, 2026
• Financial Year End: March 31, 2026

What Changes for the Business

• Designated persons and their connected relatives are prohibited from trading in Suven Life Sciences' securities during the specified closure period.
• This action is taken in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's code of conduct.

What to Track Next

• The date of the board meeting to consider the audited financial results for Q4 and FY2026 will be communicated in due course.

Summary

• Jasti Property and Equity Holdings Private Limited has acquired 31,768,764 equity shares of Suven Life Sciences Limited.
• This acquisition occurred via a preferential allotment upon the conversion of fully paid warrants.
• Following this, the total voting rights held by Jasti Property and its Persons Acting in Concert (PACs) increased to 70.15%.
• The total diluted shareholding remains at 65.38%.

Key Numbers & Dates

• Acquisition Method: Preferential allotment upon conversion of fully paid warrants.
• Shares Acquired: 31,768,764
• Voting Rights Acquired: 4.17%
• Total Voting Rights Holding (Before): 66.06%
• Total Diluted Holding (Before): 65.38%
• Total Voting Rights Holding (After): 70.15%
• Total Diluted Holding (After): 65.38%
• Date of Acquisition: March 06, 2026

What Changes for the Business

• The promoter group, Jasti Property and Equity Holdings, has significantly increased its control over Suven Life Sciences, with total voting rights rising to 70.15%.
• The acquisition consolidates the promoter's stake, reinforcing their position in the company.

⚠️ What Could Go Wrong (source-based)

• [Other] Lock-in: The entire pre-preferential allotment shareholding of the Acquirer, warrants acquired, and equity shares allotted pursuant to exercise of options shall be kept under Lock-in, as per SEBI ICDR Regulations, 2018.

What to Track Next

• Monitor the duration and terms of the lock-in period for the acquired shares.

Summary

• Suven Life Sciences Limited's Board of Directors has approved the allotment of 3,17,68,764 equity shares.
• These shares are allotted on a preferential basis upon conversion of warrants at an issue price of Rs. 134 per share.
• The company has received a total consideration of Rs. 425,70,14,376 for this allotment.

Key Numbers & Dates

• Date of Approval: March 6, 2026
• Shares Allotted: 3,17,68,764
• Issue Price: Rs. 134 per share
• Total Amount Raised: Rs. 425,70,14,376 (₹42,570.14 lakh or ₹425.70 cr)
• Pre-issue Equity Capital: Rs. 23,19,51,819 (₹2,319.52 lakh or ₹23.20 cr)
• Post-issue Equity Capital: Rs. 26,37,20,583 (₹2,637.21 lakh or ₹26.37 cr)

What Changes for the Business

• The company's paid-up equity share capital has increased following the allotment of new shares.
• Post-allotment, the paid-up equity share capital stands at Rs. 26,37,20,583, comprising 26,37,20,583 equity shares of Rs. 1/- each.

Summary

• Suven Life Sciences Limited's Board of Directors approved the allotment of 3,17,68,764 equity shares upon conversion of warrants.
• The shares were issued on a preferential basis to promoter group entity Jasti Property and Equity Holdings Private Limited.
• The company received a total consideration of Rs. 425.70 crore for this allotment.

Key Numbers & Dates

• Date of Board Approval: March 6, 2026
• Shares Allotted: 3,17,68,764 Equity Shares
• Issue Price: Rs. 134/- per share
• Total Consideration Received: Rs. 425.70 crore (Rs. 4,25,70,14,376)
• Pre-issue Paid-up Capital: Rs. 23.20 crore (23,19,51,819 shares)
• Post-issue Paid-up Capital: Rs. 26.37 crore (26,37,20,583 shares)

What Changes for the Business

• The allotment of shares increases the company's paid-up equity share capital, reflecting a higher number of outstanding shares.
• The total number of equity shares increased from 23,19,51,819 to 26,37,20,583.

What to Track Next

• No specific next steps or tracking points were mentioned in the provided text.

Suven Life Sciences Limited has officially notified the BSE Limited and the National Stock Exchange of India Limited about a newspaper advertisement published on February 19, 2026. This advertisement details a 'SPECIAL WINDOW FOR RE-LODGMENT OF TRANSFER REQUESTS OF PHYSICAL SECURITIES'. The notice, in compliance with SEBI (LODR) Regulations, 2015, also states that the information will be made available on the company's official website. This initiative aims to facilitate shareholders with physical securities to re-lodge their transfer requests within a specified window.

Suven Life Sciences Limited has responded to a clarification request from BSE Limited concerning recent price and volume movements in its stock. The company stated that it has duly notified stock exchanges about all events and information falling under Regulation 30 of SEBI (LODR) Regulations, 2015. At present, Suven Life Sciences indicated that there are no material announcements or events pending notification that would likely influence the scrip's price or volume behavior. The company believes the recent movement in its security's price and volume is primarily based on market speculation. Suven Life Sciences has requested that this clarification be disseminated on the BSE website for public information and is also uploading it on its own company website.

Suven Life Sciences Limited has submitted its Monitoring Agency Report for the quarter ended December 31, 2025, prepared by CRISIL Ratings Limited. This report details the utilization of proceeds from the company's Preferential Issue of Convertible Warrants, which aggregated to Rs 85,764.02 lakhs. CRISIL Ratings has confirmed that the utilization of these funds was in line with the objects disclosed in the offer document, with no material deviations reported. The primary objects for which the funds were raised include expenses for clinical development of molecules via its overseas subsidiary, Suven Neurosciences, Inc. (original cost Rs 40,000 lakhs), Drug Discovery Research & Development (R&D) (original cost Rs 13,000 lakhs), capital expenditure for a new R&D Centre (original cost Rs 20,000 lakhs), and General Corporate Purposes (GCP) (original cost Rs 12,764.02 lakhs).

As of December 31, 2025, the total utilized amount stood at Rs 18,062.24 lakhs, leaving a substantial unutilized balance of Rs 67,701.78 lakhs. It is also noted that Rs 27,545.30 lakhs of the total issue size is yet to be received from the warrant holders, with the option to convert into equity shares extending until December 2026. The unutilized funds have been deployed in various short-term investments such as mutual funds and fixed deposits. The report indicates no significant delays in the implementation of the stated objectives.

Suven Life Sciences Limited has made a regulatory filing, publishing its un-audited financial results for the quarter and nine months concluding on December 31, 2025. These results were advertised in the Andhra Prabha (Telugu) and Business Standard newspapers on January 30, 2026, as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company also stated that this information will be hosted on their official website.

Suven Life Sciences Limited held a Board of Directors meeting on January 29, 2026. The primary outcomes included the approval of a preferential allotment of 44,77,612 equity shares of face value ₹1 each, at an issue price of ₹134 per share. This allotment is upon the conversion of fully paid warrants and has resulted in the issuance of equity shares to non-promoter entities, namely 3P INDIA EQUITY FUND 1 and 3P INDIA EQUITY FUND 1M. The total consideration received for this allotment amounts to ₹60,00,00,008. Consequently, the company's paid-up equity share capital has increased to ₹23,19,51,819, comprising 23,19,51,819 equity shares.

In other significant personnel changes, the Board accepted the resignation of Mr. Shrenik Soni from his position as Company Secretary & Compliance Officer (Key Managerial Personnel), effective from the close of business hours on January 30, 2026, for pursuing an alternate career opportunity. Following this, the Board approved the appointment of Ms. Sangeetha Laxmi Kandari as the new Company Secretary & Compliance Officer (Key Managerial Personnel), effective from February 02, 2026. Ms. Kandari is a qualified Company Secretary with over 9 years of experience in corporate governance and secretarial functions.

Suven Life Sciences Limited held a Board of Directors meeting on January 29, 2026, where several key decisions were made. The most significant outcome was the approval of a preferential allotment of 44,77,612 equity shares, each with a face value of Rs. 1/-, at an issue price of Rs. 134/- per share. These shares were issued upon the conversion of fully paid warrants. The total consideration received for this allotment amounts to Rs. 60,00,00,008/-. The shares were allotted to two non-promoter entities: 3P INDIA EQUITY FUND 1, which received 33,58,209 shares, and 3P INDIA EQUITY FUND 1M, which received 11,19,403 shares. Consequently, the company's paid-up equity share capital has increased from 22,74,74,207 shares to 23,19,51,819 shares.

In addition to the capital raise, the Board also addressed changes in key managerial personnel. The resignation of Mr. Shrenik Soni from the position of Company Secretary & Compliance Officer (KMP) was accepted, effective from the close of business hours on January 30, 2026. Mr. Soni's resignation was stated to be for pursuing an alternate career opportunity with no other material reason. Subsequently, the Board approved the appointment of Ms. Sangeetha Laxmi Kandari as the new Company Secretary & Compliance Officer (KMP), effective from February 02, 2026. Ms. Kandari is a qualified Company Secretary with over 9 years of experience in corporate governance and secretarial functions. The meeting commenced at 11:30 AM IST and concluded at 12:40 PM IST. No financial results or forward-looking guidance were discussed as part of this announcement.

The Board of Directors of Suven Life Sciences Limited, in its meeting held on January 29, 2026, approved several key corporate actions. Primarily, the company sanctioned the preferential allotment of 44,77,612 equity shares of Rs. 1/- each at an issue price of Rs. 134/- per share. This allotment, upon conversion of fully paid warrants, is to non-promoter entities, namely 3P INDIA EQUITY FUND 1 (33,58,209 shares) and 3P INDIA EQUITY FUND 1M (11,19,403 shares), aggregating a total consideration of Rs. 60,00,00,008/-. Consequently, the company's paid-up equity share capital will increase to Rs. 23,19,51,819/- from Rs. 22,74,74,207/-.

In addition to the fundraising, the Board took note of the resignation of Mr. Shrenik Soni from his position as Company Secretary & Compliance Officer (Key Managerial Personnel), effective close of business hours on January 30, 2026, citing pursuit of an alternate career opportunity. Following this, the Board approved the appointment of Ms. Sangeetha Laxmi Kandari as the new Company Secretary & Compliance Officer (Key Managerial Personnel), effective February 02, 2026. Ms. Kandari brings over 9 years of experience in corporate governance, secretarial, and compliance functions. The Board meeting commenced at 11:30 AM IST and concluded at 12:40 PM IST.

Suven Life Sciences Limited announced the outcome of its Board of Directors meeting held on January 29, 2026. The Board approved the allotment of 44,77,612 equity shares at an issue price of ₹134 per share, totaling ₹60,00,00,008 (₹60.00 Cr), through a preferential allotment upon the conversion of fully paid warrants. These shares were issued to non-promoter entities, 3P INDIA EQUITY FUND 1 and 3P INDIA EQUITY FUND 1M. As a result of this allotment, the company's paid-up equity share capital increased to ₹23,19,51,819 consisting of 23,19,51,819 equity shares. In terms of personnel changes, the Board accepted the resignation of Mr. Shrenik Soni from his position as Company Secretary & Compliance Officer (Key Managerial Personnel), effective January 30, 2026, stating he is pursuing an alternate career opportunity. Concurrently, Ms. Sangeetha Laxmi Kandari was appointed as the new Company Secretary & Compliance Officer (KMP), effective February 02, 2026. Ms. Kandari brings over nine years of experience in corporate governance and secretarial functions. The Board meeting commenced at 11:30 AM IST and concluded at 12:40 PM IST. No financial results, performance metrics, future outlook, or guidance were part of this announcement.

Suven Life Sciences Limited - Q3 FY26 Financial Results and Key Updates

Suven Life Sciences Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025, following a board meeting held on January 29, 2026. The company reported year-over-year growth in revenue from operations but faced a significant widening of consolidated net losses, primarily driven by substantial Research & Development (R&D) expenses.

Quarterly/Annual Results

For the quarter ended December 31, 2025, Suven Life Sciences reported revenue from operations of ₹280.87 Lakhs on both standalone and consolidated bases, marking a year-over-year increase. Despite revenue growth, the company incurred a net loss of ₹1,347.17 Lakhs on a standalone basis. The consolidated net loss escalated to ₹10,192.18 Lakhs for the quarter, a substantial increase from the ₹3,911.66 Lakhs loss reported in the corresponding quarter of the previous year. This widening loss is largely attributable to high R&D expenses, which amounted to ₹20,585.69 Lakhs for the nine months ended December 31, 2025, on a consolidated basis. Basic Earnings Per Share (EPS) for the quarter stood at ₹(0.60) standalone and ₹(4.55) consolidated.

Guidance & Concall Commentary

The company did not provide specific forward-looking financial guidance in this announcement. However, it highlighted progress in its clinical development pipeline for Central Nervous System (CNS) disorders. Key ongoing or upcoming clinical trials include Phase 3 studies for SUVN-502 (Masupirdine) for agitation and aggression in Alzheimer's type dementias, preparation for Phase 3 of SUVN-G3031 (Samelisant) for EDS in Narcolepsy, and ongoing Phase 2B studies for SUVN-911 (Ropanicant) and Phase 1 for SUVN-I6107. Additionally, an Investigational New Drug (IND) submission for SUVN-D4010 (Usmarapride) for cognitive dysfunction in major depressive disorder was completed, with a Phase 2 study planned for calendar 2026. The company also reported the grant of 6 patents during the period.

Financials

• Income Statement: Revenue shows positive YoY growth, but high R&D expenditure continues to be the primary driver of significant operating losses.
• Balance Sheet: The paid-up equity share capital has increased following the allotment of new shares. The company completed the conversion of warrants into 44,77,612 equity shares at an issue price of ₹134 per share, raising ₹6,000.00 Lakhs (₹60 Cr). This is part of a larger preferential issue, where ₹58,218.72 Lakhs has been received to date, with ₹40,156.48 Lakhs outstanding.
• Cash Flow: Specific cash flow details were not provided in the announcement.
• Ratios: Negative Basic EPS for the quarter as detailed above.

Key Events

The board of directors approved the allotment of equity shares upon the conversion of warrants. Mr. Shrenik Soni resigned as Company Secretary & Compliance Officer (Key Managerial Personnel), effective January 30, 2026. Ms. Sangeetha Laxmi Kandari has been appointed as the new Company Secretary & Compliance Officer, effective February 02, 2026. Six patents were granted during the reporting period.

Outlook

Suven Life Sciences remains strategically focused on its long-term R&D objectives for developing novel therapies for CNS disorders. The immediate outlook is characterized by continued substantial R&D investment and progress in clinical trials. The impact of the recently completed capital raise on funding these operations and the timeline for achieving profitability are key factors for investors to monitor.

Suven Life Sciences Limited has issued a regulatory filing announcing that a meeting of its Board of Directors will be held on Thursday, January 29, 2026. The meeting is scheduled to take place at the company's registered office in Hyderabad. The primary agenda for this board meeting is to consider, approve, and take on record the un-audited financial results of the company, both on a standalone and consolidated basis, for the third quarter and the first nine months of the fiscal year 2025-2026, which ended on December 31, 2025. Furthermore, the company has informed that the trading window for dealing in its equity shares by all designated persons and their relatives has been closed from January 1, 2026, as per the company's PIT Code. This closure will persist until 48 hours after the declaration of the aforementioned financial results.

Suven Life Sciences Limited has submitted its Monitoring Agency (MA) Report for the quarter ended December 31, 2025, detailing the utilization of funds from its preferential issue of convertible warrants. The report, issued by CRISIL Ratings Limited, confirms that the utilized funds align with the company's stated objectives, including clinical development and CAPEX for a new R&D center.

The current announcement is a regulatory filing and does not contain specific financial results. However, past performance indicated in the provided context reveals significant net losses in recent quarters, primarily due to high R&D expenses, despite revenue growth in some instances.

No new guidance is provided in this update. The company's focus remains on its drug discovery pipeline and clinical development.

The MA report confirms utilization of Rs 85,764.02 Lakh from the preferential issue. Of this, Rs 5,424.12 Lakh was utilized during the quarter, directed towards clinical development of molecules, drug discovery R&D, and CAPEX for a new R&D center. A substantial Rs 80,339.90 Lakh remains unutilized and invested in money market instruments.

Key events include the submission of the MA Report for the quarter ended December 31, 2025, by CRISIL Ratings Limited. Separately, the company achieved a significant milestone by completing 100% patient enrollment in its Phase-2b clinical trial for Ropanicant (for MDD) in the US, ahead of schedule. The trading window for the company's shares has been closed from January 01, 2026, and will remain shut for 48 hours after the announcement of Q3 FY26 results.

Outlook: The successful completion of patient enrollment for the Ropanicant Phase-2b trial is a positive development, with topline data expected by May 2026. The substantial unutilized funds from the preferential issue provide financial flexibility for continued R&D and operational activities, mitigating short-term liquidity concerns. However, the long-term profitability outlook will depend on the success of its drug pipeline and commercialization efforts, given the historical net losses.

News Crux

Suven Life Sciences Limited reported challenging financial results for Q1 FY25 and Q2 FY26, marked by widening net losses, primarily driven by substantial Research and Development (R&D) expenditures. While Q1 FY25 saw revenue growth, the losses escalated significantly. Q2 FY26 performance was further impacted by a sharp decline in consolidated revenue. Amidst these financial headwinds, the company continues to make notable progress in its drug discovery pipeline, particularly with its Phase-2b clinical trial for Ropanicant.

Quarterly/Annual Results

• Q1 FY25 (ended June 30, 2025): Standalone revenue increased by 85.56% year-on-year (YoY) to ₹186.67 Lakhs. However, the standalone net loss widened to ₹1,477.87 Lakhs from ₹766.59 Lakhs in the prior year period. On a consolidated basis, revenue was reported at ₹186.67 Lakhs, with the net loss escalating to ₹5,151.69 Lakhs (compared to ₹2,803.97 Lakhs YoY). This significant increase in consolidated loss was largely attributed to a 66.51% YoY surge in R&D expenses, reaching ₹4,148.84 Lakhs. Consequently, consolidated Earnings Per Share (EPS) deteriorated to ₹(2.36) from ₹(1.29) YoY.
• Q2 FY26 (ended September 30, 2025): Consolidated revenue declined substantially by 64.3% YoY to ₹91.92 Lakhs. The consolidated net loss widened further to ₹7,730.99 Lakhs. The company also received a Monitoring Agency (MA) report for its preferential issue of convertible warrants, detailing the utilization of Rs 5,424.12 Lakhs out of the Rs 85,764.02 Lakhs raised.

Guidance & Concall Commentary

No specific financial guidance or commentary from concalls regarding these periods was provided in the news snippets.

Financials (Income, Balance Sheet, Cash Flow, Ratios)

• Income Statement Drivers: High R&D expenditure remains a key factor contributing to persistent net losses. Recent results show declining revenues (Q2 FY26) and widening losses.
• Balance Sheet: The company raised substantial funds through a preferential issue of convertible warrants (Rs 85,764.02 Lakhs). As of September 2025, investments stood at ₹999 Lakhs, indicating significant liquidity, with a large portion (₹80,339.90 Lakhs) invested in money market funds and debt instruments. The company data indicates zero borrowings, implying a debt-free status.
• Cash Flow: Specific details for recent quarters were not available in the provided news.
• Key Ratios: Historical data shows consistently negative Return on Equity (ROE) and Return on Capital Employed (ROCE).

Key Events

• Ropanicant Clinical Trial: The company achieved its milestone of 100% patient enrollment in its Phase-2b clinical trial for Ropanicant, a novel nicotinic α4β2 receptor antagonist for Major Depressive Disorder (MDD). This was accomplished in the US ahead of schedule, with the last patient out expected in February 2026 and topline data readout anticipated by May 2026.
• Preferential Issue of Warrants: A Monitoring Agency report confirmed the utilization of funds raised from warrants towards clinical development, R&D, and Capital Expenditure (CAPEX) for a new R&D center, alongside general corporate purposes.
• 36th Annual General Meeting (AGM): Held on August 22, 2025, where shareholders approved the audited standalone and consolidated financial statements for FY25 and other resolutions, indicating shareholder confidence.
• Trading Window Closure: The company announced the closure of its trading window from January 01, 2026, until 48 hours after the declaration of financial results for the quarter ending December 31, 2025 (Q3 FY26), adhering to SEBI regulations.

Outlook

The company's long-term outlook is critically linked to the success of its drug discovery pipeline, especially the Ropanicant trial. Near-term financial performance remains a concern due to ongoing losses and substantial R&D investments. The substantial funds raised provide a cushion for continued research and development activities.

Suven Life Sciences Limited has announced a significant advancement in its clinical development pipeline with the achievement of the 100% patient enrollment milestone for its Phase-2b clinical trial of Ropanicant. This trial, focused on treating Major Depressive Disorder (MDD), has successfully enrolled its target number of approximately 195 patients across 35 sites in the USA, notably completing this phase more than two months ahead of schedule.

The Phase-2b study is a randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of Ropanicant, a novel nicotinic α4β2 receptor antagonist, in patients with MDD. The treatment duration is six weeks, with efficacy measured by the Montgomery-Asberg Depression Rating Scale (MADRS). The rapid recruitment pace highlights strong engagement from investigators and patients.

Management expressed optimism: Mr. Venkat Jasti, Chairman and Managing Director, conveyed gratitude for the commitment shown by patients, caregivers, investigators, and the clinical team, emphasizing the progress towards evaluating Ropanicant's potential. Dr. Ramakrishna Nirogi, President and CSO, highlighted the high interest in Ropanicant due to its novel mechanism of action and potential to transform lives affected by MDD, anticipating outcome presentation by May 2026.

Safety data is under continuous monitoring, with no significant concerns reported to date. The company anticipates the last patient out (LPO) by the end of February 2026, with topline efficacy and safety results expected by May 2026.

Ropanicant (SUVN-911) has demonstrated efficacy in animal models and may offer advantages over current treatments, including rapid onset, reduced sexual dysfunction, and enhanced cognitive function. Suven Life Sciences fully owns the intellectual property rights for Ropanicant. The company's broader focus is on discovering and developing innovative medicines for Central Nervous System (CNS) disorders, with a portfolio including other clinical-stage assets for Alzheimer's disease, sleep disorders, Parkinson's disease, and more.

This SSL Research morning update for December 5, 2025, provides a snapshot of market expectations and key actionable news for investors. The market is anticipated to open flat ahead of the RBI MPC policy outcome, with attention on rate-sensitive sectors like Auto, Banks, NBFCs, and Realty. Global markets showed mixed performance, with Wall Street ending mixed and Asian indices largely trading in the red.

Significant corporate actions highlighted include British American Tobacco's intention to offload shares worth nearly Rs 3,000 crore in ITC Hotels, a move deemed negative in the short to medium term. Positively, Shriram Pistons & Rings Ltd is set to acquire 100% stake in Antolin Lighting India and Grupo Antolin India for an enterprise value of approximately Rs 1,670 crore, expanding its presence in automotive interior and lighting solutions.

Other key developments include positive medium to long-term prospects for Seamec and Lloyds Engineering due to new pacts in offshore vessel charter and radar technology development, respectively. RailTel Corp and Zen Tech have received work orders and supply orders worth Rs 63.9 crore and Rs 120 crore, respectively, from government entities, while Diamond Power secured a Rs 748 crore order from Adani Green for cable supply. Deepak Nitrite's arm commenced operations at a new Nitric acid plant, a neutral short-term development. Excelsoft Tech's partnership with AQA for AI R&D is viewed positively for the medium to long term.

The report also details the subscription status of ongoing IPOs for Meesho, Aequs, and Vidya Wires, with Aequs showing strong subscription figures. Promoters made significant purchases in TGV Sraac, Greenply Industries, Aarti Pharmalabs, Usha Martin, and Maharashtra Seamless. Numerous stocks experienced price band revisions from 10% to 20% or 5% to 10%. Important corporate actions like ex-demerger dates, ex-rights issues, and shares exiting anchor lock-in periods are listed. Fund flow data for December 4th shows net inflows from DIIs (Rs +3,661.1 crore) and net outflows from FIIs (Rs -1,994.2 crore).

Suven Life Sciences Limited has submitted a Monitoring Agency (MA) Report, dated November 12, 2025, prepared by CRISIL Ratings Limited, for the quarter ended September 30, 2025. This report, submitted to BSE Limited and the National Stock Exchange of India Limited, pertains to the utilization of proceeds from the company's Preferential Issue of Convertible Warrants.

The issue size stands at Rs 85,764.02 Lakh. The report details that Rs 5,424.12 Lakh was utilized during the quarter for various approved objects. These include: Rs 2,616.27 Lakh for the clinical development of molecules via its subsidiary Suven Neurosciences, Inc.; Rs 1,172.80 Lakh for Drug Discovery Research & Development (R&D); Rs 92.98 Lakh for CAPEX towards a new R&D Centre; and Rs 1,542.08 Lakh for General Corporate Purposes (GCP). The report confirms that this utilization is in line with the disclosures made in the offer document and the notice to shareholders dated May 14, 2025.

As of September 30, 2025, a significant amount of Rs 80,339.90 Lakh of the issue proceeds remains unutilized. These unutilized funds have been deployed in short-term investments, primarily money market funds and institutional debt funds, with a total market value of Rs 25,624.75 Lakh and reported earnings of Rs 326.17 Lakh.

CRISIL Ratings, in its report, stated that there were no deviations from the objects of the issue and that all utilization was as per disclosures. The agency affirmed adherence to the Monitoring Agency Agreement dated May 15, 2025, and relevant SEBI regulations, without finding any material deviations over earlier reports. The report also included standard disclaimers regarding the MA's role, emphasizing that it does not perform an audit and relies on information provided by the issuer and its auditors.

The issue period was from June 21, 2025, to June 30, 2025. The remaining 75% of the issue amount is expected to be received by December 2026 as warrant holders exercise their conversion options.

Suven Life Sciences Limited has issued a notification to the NSE and BSE regarding a newspaper advertisement published on November 12, 2025. This advertisement, appearing in Business Standard and Andhra Prabha, announces the company's un-audited financial results for the quarter and half-year ended September 30, 2025, in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company also stated that this information will be hosted on its website.

Suven Life Sciences Limited announced its un-audited financial results for the quarter and half-year ended September 30, 2025. The company reported significant net losses on a consolidated basis. For the quarter ended September 30, 2025, consolidated revenue from operations was ₹91.92 Lakhs, a sharp decrease of 64.3% YoY from ₹257.29 Lakhs in the same period last year. The consolidated net loss for the quarter widened to ₹7,730.99 Lakhs, compared to a loss of ₹4,964.38 Lakhs in Q2 FY25. Diluted EPS stood at ₹(3.48).

The half-year ended September 30, 2025, also showed a decline in revenue and an increase in losses. Consolidated revenue was ₹278.59 Lakhs (down 22.2% YoY from ₹357.89 Lakhs), and the net loss for the half-year was ₹12,882.68 Lakhs (vs. ₹7,768.35 Lakhs in H1 FY25), with diluted EPS at ₹(5.80).

A primary driver for these losses is the substantial R&D expenditure, which stood at ₹11,180.97 Lakhs for H1 FY26, an increase of 54.2% from ₹7,250.36 Lakhs in H1 FY25. The balance sheet reflects substantial equity of ₹28,127.41 Lakhs and significant investments (₹24,671.26 Lakhs in mutual funds). Consolidated operating cash flow for H1 FY26 was a negative ₹10,338.01 Lakhs. Financing activities saw a significant inflow of ₹29,954.28 Lakhs from a preferential issue of convertible warrants, raising a total of ₹30,673.43 Lakhs, with ₹5,424.12 Lakhs utilized as of September 30, 2025.

Key developments include the grant of 17 patents across various countries during the period. The company also provided an update on its clinical development pipeline for Central Nervous System (CNS) disorders, with several drug candidates (e.g., SUVN-502, SUVN-G3031, SUVN-911) in advanced clinical trial phases (Phase 2B, Phase 3, Phase 1) with expected completion dates mostly by end of 2026. The company's outlook remains focused on drug discovery and development for unmet medical needs.

Suven Life Sciences Limited has formally notified the stock exchanges, BSE and NSE, about an upcoming Board Meeting. This meeting is scheduled to be held on Tuesday, November 11, 2025, at the company's registered office in Hyderabad. The central objective of this board meeting is to review, consider, and approve the un-audited financial results for both standalone and consolidated entities. These results pertain to the fiscal quarter and the half-year that concluded on September 30, 2025. It is important to note that this announcement does not contain any specific financial performance data, such as revenue, profit, margins, or Earnings Per Share (EPS) for the period under review. Additionally, there is no information provided regarding management guidance, future outlook, or commentary on the company's performance or strategic direction. Consequently, there are no details on balance sheet figures, cash flow statements, key financial ratios, or any in-depth financial analysis available in this notice. The company also confirmed that its trading window for dealing in equity shares, which was closed from October 1, 2025, will continue to remain closed until 48 hours after the official declaration of these financial results, in strict adherence to the company's Insider Trading (Prohibition) Code and SEBI regulations. This constitutes a procedural announcement, with the actual financial performance details expected to be disclosed following the board meeting on November 11, 2025.

Suven Life Sciences Limited has made a regulatory filing with the stock exchanges, BSE and NSE, concerning its compliance status for the quarter that concluded on September 30, 2025. The company's communication, dated October 9, 2025, confirms that the requisite information regarding the dematerialization and rematerialization of its securities has been duly processed and submitted. KFin Technologies Limited, serving as the company's appointed Registrar & Transfer Agent (RTA), has been instrumental in providing these details to the exchanges. This action is in strict adherence to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, a critical rule for listed entities managing their shareholding structures.

The filing includes confirmation letters from KFin Technologies Limited, dated October 2, 2025. These letters serve as an official certification to the stock exchanges, as well as to the depositories like NSDL and CDSL, verifying that all obligations under the specified SEBI regulation have been met for the reporting quarter. The nature of this update is purely procedural and operational, focused on maintaining regulatory compliance and ensuring the integrity of the share registry. There are no financial results, earnings announcements, guidance, significant orders, expansions, or other material corporate actions discussed or disclosed in this notification. The document primarily serves to assure stakeholders and regulatory bodies that the company is up-to-date with its reporting requirements related to the movement between physical and electronic share formats.

Suven Life Sciences Limited has formally announced the closure of its trading window for dealing in the company's securities. This directive, communicated to the National Stock Exchange of India Limited (NSE) and BSE Limited on September 25, 2025, is effective from October 1, 2025. The trading window will remain shut until a period of 48 hours following the public declaration of the company's financial results for the quarter ending September 30, 2025 (Q2 FY26). This closure is in strict compliance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The notification explicitly advises all Designated Persons and their relatives against trading in Suven Life Sciences' securities during this stipulated period to prevent potential insider trading. No financial performance data, future outlook, or other operational details were disclosed in this communication.

The 36th Annual General Meeting (AGM) of Suven Life Sciences Limited was held on Friday, August 22, 2025, via Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The meeting commenced at 11:30 a.m. IST and concluded at 12:38 p.m. IST with e-voting, attended by 60 members. Key agenda items included the adoption of the audited standalone and consolidated financial statements for the fiscal year ended March 31, 2025, the re-appointment of a director (Smt. Sudharani Jasti), and the appointment of secretarial auditors. The Chairman confirmed that the Auditors' Report and Secretarial Audit report contained no qualifications or adverse remarks. Shareholders were informed about the remote e-voting period (August 18-21, 2025) and the e-voting facility during the AGM. The Scrutinizer's Report confirmed that all resolutions passed with a significant majority, with over 99.99% of votes in favour for the adoption of financial statements and appointment of secretarial auditors, and over 99.996% for the director re-appointment. This filing primarily details the procedural outcome and shareholder voting results of the AGM, without providing specific financial performance data or forward-looking guidance.

Suven Life Sciences Limited conducted its 36th Annual General Meeting (AGM) on Friday, August 22, 2025, via Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The meeting commenced at 11:30 a.m. IST with a quorum present, chaired by Shri Venkateswarlu Jasti, Chairman & MD. The proceedings confirmed that the Auditors' Report and Secretarial Audit report had no qualifications. Shareholders were informed about the availability of audited financial statements for the year ended March 31, 2025, along with Directors' and Auditors' reports. The company provided remote e-voting facilities from August 18 to August 21, 2025, and an electronic voting opportunity during the AGM for those present. Shareholders had the opportunity to ask questions and receive responses from management. Three ordinary resolutions were transacted: 1. Adoption of the audited standalone and consolidated financial statements for FY 2024-25. 2. Re-appointment of Smt. Sudharani Jasti, who retires by rotation, as a director. 3. Appointment of Secretarial Auditors for the Company. The scrutinizer's report confirmed that all three resolutions secured overwhelming support, passing with percentages ranging from 99.996% to 99.999% in favour, indicating strong shareholder endorsement. The results were declared by the Company Secretary based on the scrutinizer's report.

MIPCO Seamless Rings (Gujarat) Limited: For the quarter ended June 30, 2025, the company reported unaudited results with Total Income from Operations of ₹(8.34) lakh, Net Profit/(Loss) after tax of ₹(8.34) lakh, and EPS of ₹(0.23). Comparatives from the text show Total Income of ₹2.18 lakh (Q4 FY25) and ₹(7.19) lakh (Q1 FY25); Net Profit/(Loss) of ₹2.18 lakh (Q4 FY25) and ₹(7.19) lakh (Q1 FY25); and EPS of ₹0.06 (Q4 FY25) and ₹(0.20) (Q1 FY25).

BKV Industries Limited: Announced Q1 FY26 un-audited standalone results. Total Income was ₹20.32 lakh, compared to ₹20.79 lakh in the previous quarter and ₹20.03 lakh in the corresponding prior year quarter. The company reported a Net Profit/(Loss) after tax of ₹(2.02) lakh, versus ₹(0.07) lakh in the previous quarter and ₹2.21 lakh in the prior year quarter. Basic EPS was ₹(0.01), compared to nil in the previous quarter and ₹0.01 in the prior year quarter.

Raminfo Limited: Disclosed Q1 FY26 un-audited results. Consolidated Total Revenue from Operations was ₹1,162.06 lakh, up from ₹798.43 lakh in the previous quarter but down from ₹2,058.84 lakh in the corresponding prior year quarter. Consolidated Net Profit after tax stood at ₹5.79 lakh, a significant decrease from ₹76.64 lakh in the previous quarter and ₹171.06 lakh in the same period last year. Consolidated Basic EPS was ₹0.08, compared to ₹1.02 in the previous quarter and ₹2.27 in the prior year quarter.

Suven Life Sciences Limited: Issued a formal notification to the stock exchanges regarding the publication of its un-audited financial results for the quarter ended June 30, 2025. No specific financial figures were included in this announcement.

Suryavanshi Spinning Mills Limited announced its unaudited financial results for the quarter ended June 30, 2025. The company reported total income from operations of ₹135.6 lakhs, a significant year-on-year decrease of 30.9% from ₹196.42 lakhs in Q1 FY24. The net profit after tax for the quarter was a loss of ₹20.75 lakhs, a stark contrast to the profit of ₹530.58 lakhs recorded in the same period last year. Correspondingly, the diluted Earnings Per Share (EPS) turned negative at ₹-0.42, compared to ₹10.81 in Q1 FY24. This indicates a substantial deterioration in financial performance compared to the previous year's quarter.

In separate news, Midwest Gold Limited is facing significant financial challenges indicated by multiple actions under the Securitisation and Reconstruction of Financial Assets and Enforcement of Security Interest (SARFAESI) Act, 2002. JM Financial Home Loans Limited has taken possession of a mortgaged property and is proceeding with its sale via private treaty due to a loan default amounting to ₹36.21 lakhs. Additionally, Tata Capital Housing Finance Limited has issued demand notices under SARFAESI for loan defaults by Mr. Lakkan Subramanyam (₹22.18 lakhs) and Mr. BANALA NAGA RAJU (₹28.18 lakhs). These developments suggest potential asset liquidation and severe financial strain.

Suven Life Sciences Limited issued a notice regarding its 36th Annual General Meeting (AGM) scheduled for August 14, 2025, along with e-voting information.

Sree Rayalaseema Hi-Strength Hypo Limited is participating in the 'Saksham Niveshak' campaign by the IEPFA and MCA, aimed at encouraging shareholders to update their details and claim any unpaid or unclaimed dividends.

Suven Life Sciences reported its unaudited financial results for the quarter ended June 30, 2025 (Q1 FY26). Consolidated revenue stood at INR 24.67 million, marking a significant year-over-year decrease of 50.8% compared to INR 50.14 million in Q1 FY25. The company posted a net loss after tax of INR 515.17 million for the quarter, an increase of 83.9% from the net loss of INR 280.40 million in the corresponding prior-year period. Consequently, Earnings Per Share (EPS) declined to (INR 2.36) from (INR 1.29) YoY. R&D and operational expenses increased to INR 526.15 million from INR 315.45 million YoY. The company successfully completed a fund-raising program worth INR 8576.40 million via preferential issue of convertible warrants. Updates on the clinical development pipeline include progress on SUVN-502 (Phase 3, 43% enrolled, end FY26 completion), SUVN-G3031 (Phase 3 prep, start Q2 FY26), SUVN-911 (Phase 2B initiated, July 2025 enrollment, FY27 completion), SUVN-D4010 (Phase 2 planning, FY26 initiation), and SUVN-I6107 (Phase 1 ongoing, end FY26 completion). No specific guidance or balance sheet/cash flow details were provided in this release.

Suven Life Sciences Limited announced its Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2025. The company reported robust year-on-year revenue growth, but experienced a significant expansion in net losses.

**Quarterly Performance (Q1 FY25 vs Q1 FY24):

• Standalone:**
  • Revenue from operations increased by 85.56% YoY to ₹186.67 Lakhs from ₹100.60 Lakhs.
  • Net Profit/Loss: The company reported a net loss of ₹1,477.87 Lakhs, a substantial increase from a loss of ₹766.59 Lakhs in the previous year's quarter.
  • Earnings Per Share (EPS) deteriorated to ₹(0.68) from ₹(0.35) YoY.

Consolidated:

• Revenue from operations was reported at ₹186.67 Lakhs, showing a YoY increase of 85.56% (same as standalone).
• Net Profit/Loss: The consolidated net loss widened significantly to ₹5,151.69 Lakhs, compared to a loss of ₹2,803.97 Lakhs in Q1 FY24.
• Earnings Per Share (EPS) declined to ₹(2.36) from ₹(1.29) YoY.

Financials and Key Drivers:

• The primary driver for the consolidated loss expansion was the sharp increase in R&D expenses, which grew by 66.51% YoY to ₹4,148.84 Lakhs in Q1 FY25 from ₹2,491.87 Lakhs in Q1 FY24.
• Other Comprehensive Income (OCI) also contributed to the total comprehensive loss.
• The company noted the recognition of employee benefit expenses related to ESOPs and received ₹106.43 Lakhs from option exercises.
• A significant preferential issue of convertible warrants was approved by the board and shareholders, with ₹29,165.93 Lakhs received as upfront and balance payments as of June 30, 2025.

Outlook and Other Information:

• No specific management guidance or outlook was provided in the enclosed results.
• Patent updates are available on the company's website.
• The company operates in a single business segment: Research & Development.

Suven Life Sciences Limited has issued a regulatory filing intimating that its Board of Directors will convene a meeting on Wednesday, August 13, 2025. The meeting is scheduled to be held at the company's registered office in Banjara Hills, Hyderabad. The key purpose of this board meeting is to consider and approve, among other things, the un-audited financial results for the first quarter ended June 30, 2025, on both standalone and consolidated bases. Concurrently, the company has informed that the trading window for dealing in its equity shares has been closed for all designated persons and their relatives since July 1, 2025, as per the company's PIT Code. This closure will persist up to 48 hours following the declaration of the aforementioned financial results. No specific financial figures, performance metrics, guidance, or details about the outlook were disclosed in this notice, as it serves as a preliminary intimation for the upcoming results announcement.